JP2014518898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518898A5 JP2014518898A5 JP2014514452A JP2014514452A JP2014518898A5 JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5 JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014514452 A JP2014514452 A JP 2014514452A JP 2014518898 A5 JP2014518898 A5 JP 2014518898A5
- Authority
- JP
- Japan
- Prior art keywords
- mcam
- antigen
- binds
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493780P | 2011-06-06 | 2011-06-06 | |
| US61/493,780 | 2011-06-06 | ||
| US201161527481P | 2011-08-25 | 2011-08-25 | |
| US61/527,481 | 2011-08-25 | ||
| PCT/US2012/000274 WO2012170071A1 (en) | 2011-06-06 | 2012-06-06 | Mcam antagonists and methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518898A JP2014518898A (ja) | 2014-08-07 |
| JP2014518898A5 true JP2014518898A5 (enExample) | 2015-07-30 |
| JP6305919B2 JP6305919B2 (ja) | 2018-04-04 |
Family
ID=46354461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514452A Expired - Fee Related JP6305919B2 (ja) | 2011-06-06 | 2012-06-06 | Ｍｃａｍアンタゴニスト及び治療の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20140314744A1 (enExample) |
| EP (1) | EP2718327A1 (enExample) |
| JP (1) | JP6305919B2 (enExample) |
| CA (1) | CA2836373A1 (enExample) |
| HK (1) | HK1197072A1 (enExample) |
| WO (1) | WO2012170071A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2676962C (en) * | 2009-06-09 | 2020-11-10 | Centre Hospitalier De L'universite De Montreal | Mcam modulation and uses thereof in the management of neuroinflammatory conditions |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
| CA2938933A1 (en) * | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| JP6728053B2 (ja) * | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗ｍｃａｍ抗体及び関連する使用方法 |
| JP2017510627A (ja) | 2014-03-13 | 2017-04-13 | プロセナ バイオサイエンシーズ リミテッド | 多発性硬化症の併用治療 |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153955A1 (en) * | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| AU2002252444A1 (en) * | 2001-03-23 | 2002-10-08 | Board Of Regents, The University Of Texas System | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors |
| TWI334439B (en) * | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| CA2472154A1 (en) * | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Use of antibodies against the muc18 antigen |
| EP1467756A4 (en) | 2001-12-28 | 2007-03-21 | Abgenix Inc | METHODS OF USING ANTI-MUC18 ANTIBODIES |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| CN101245101B (zh) * | 2008-01-31 | 2013-10-16 | 中国科学院生物物理研究所 | 抗人cd146的单克隆抗体，包含其的组合物，检测可溶性cd146的方法 |
| US8293468B2 (en) | 2009-06-10 | 2012-10-23 | Centre Hospitalier De L'université De Montréal | MCAM modulation and uses thereof |
-
2012
- 2012-06-06 WO PCT/US2012/000274 patent/WO2012170071A1/en not_active Ceased
- 2012-06-06 JP JP2014514452A patent/JP6305919B2/ja not_active Expired - Fee Related
- 2012-06-06 CA CA2836373A patent/CA2836373A1/en not_active Abandoned
- 2012-06-06 US US14/124,620 patent/US20140314744A1/en not_active Abandoned
- 2012-06-06 EP EP12729758.8A patent/EP2718327A1/en not_active Withdrawn
- 2012-06-06 HK HK14110255.3A patent/HK1197072A1/xx unknown
-
2019
- 2019-11-21 US US16/691,525 patent/US20200165336A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518898A5 (enExample) | ||
| RU2018132044A (ru) | Антитела против тау | |
| WO2015091853A3 (en) | Human anti-cd40 human antibodies | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| EP3004168A4 (en) | Chimeric antigen receptor-targeting monoclonal antibodies | |
| IL229618B (en) | Isolated antibody that binds fcrn | |
| PH12015501505B1 (en) | Antibodies that bind to tl1a and their uses | |
| IL267382A (en) | Oncostatin m receptor antigen binding proteins | |
| WO2014189973A3 (en) | Anti-transferrin receptor antibodies and methods of use | |
| PT2977385T (pt) | Anticorpos humanizados, específicos da forma protofibrilar do peptídeo beta-amiloide | |
| IL221408B (en) | Monoclonal antibodies against c-met | |
| BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
| EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| JP2013539454A5 (enExample) | ||
| PT3016681T (pt) | Anticorpos humanizados ou quiméricos cd3 | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| EP2771031A4 (en) | ALPHA SYNNUCLEIN DETECTING HUMANIZED ANTIBODIES | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| CA2872308A1 (en) | Novel ha binding agents | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| IL236549A0 (en) | Antibodies to a beta c-terminal or central epitope and uses thereof | |
| IL258914A (en) | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof | |
| EP2949750A4 (en) | ANTIBODY-BINDING PEPTIDE |